Hikal Ltd
Hikal Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #45 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Pharmaceutical Business: Expected low-teens revenue growth (12%-14%) in FY '26, recovering from volume deferrals due to US FDA OAI status. The Pharmaceutical segment faced deferment of revenues due to the US FDA OAI status but expects recovery in Q2 and Q3 of FY '26, with no anticipated overall revenue or margin impact for the full year.
From Hikal Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Pharmaceutical Business: Expected low-teens revenue growth (12%-14%) in FY '26, recovering from volume deferrals due to US FDA OAI status. Commercial production and validation of new molecules anticipated by FY '26-FY '28.
- Crop Protection Business: Flattish revenue growth expected in FY '26 amid global overcapacity and pricing pressures, with seasonal volume recovery anticipated in H2 FY '26.
- Animal Health Segment: Steady progress with commercial launches planned from FY '26 onwards; diversification and portfolio expansion expected to drive long-term growth.
- CDMO Segment: Robust and diversified pipeline with commercial revenues expected toward end of FY '26; growth driven by China-plus-one strategy and global innovators.
2 more points from Hikal Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Hikal Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Q1 FY26 CAPEX was Rs. 31 crores focused on debottlenecking, regulatory upgrades, and CDMO capacity augmentation.
- Full-year CAPEX guidance remains Rs. 200 crores, with disciplined allocation towards high ROI projects aligned with long-term growth.
- Ongoing facility and quality control upgrades as part of corrective measures post US FDA OAI status; includes some capital expenses.
- Conversion of part of the specialty chemicals plant into Pharma and Animal Health production; refitting in progress with commercial production expected in 6-9 months.
2 more points from Hikal Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hikal Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Customers have deferred shipments due to the OAI status at the Bangalore facility; however, no orders have been canceled.
- Deferred revenue is approximately Rs. 50 crores from Q1, expected to be realized in Q2 and Q3.
- Customers have reaffirmed their commitment to pick up products within Q2 and Q3.
- The company is confident of recovering deferred volumes by end of the second and third quarters of FY '26.
2 more points from Hikal Ltd's call on order book
Create a free account to keep reading this call
Hikal Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹519 Cr, net profit ₹14 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hikal's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG LifeScience. (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharma. (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Labs. (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Hikal Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Hikal Ltd Q1 FY26 results?
Pharmaceutical Business: Expected low-teens revenue growth (12%-14%) in FY '26, recovering from volume deferrals due to US FDA OAI status. The Pharmaceutical segment faced deferment of revenues due to the US FDA OAI status but expects recovery in Q2 and Q3 of FY '26, with no anticipated overall revenue or margin impact for the full year.
What is Hikal Ltd share price analysis?
Hikal Ltd currently shows a neutral. The stock trades at a P/E of 63.4 with a market cap of ₹2,688 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hikal Ltd planning capital expenditure?
Q1 FY26 CAPEX was Rs.
Keep Hikal Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.